Compare ORCL & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORCL | JNJ |
|---|---|---|
| Founded | 1977 | 1886 |
| Country | United States | United States |
| Employees | 162000 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.9B | 546.9B |
| IPO Year | 2005 | 2003 |
| Metric | ORCL | JNJ |
|---|---|---|
| Price | $186.63 | $229.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 20 |
| Target Price | ★ $260.11 | $238.20 |
| AVG Volume (30 Days) | ★ 20.7M | 6.6M |
| Earning Date | 06-10-2026 | 04-14-2026 |
| Dividend Yield | 1.22% | ★ 2.36% |
| EPS Growth | 16.98 | ★ 90.50 |
| EPS | ★ 4.38 | 2.14 |
| Revenue | ★ $57,399,000,000.00 | N/A |
| Revenue This Year | $19.50 | $6.63 |
| Revenue Next Year | $31.91 | $7.43 |
| P/E Ratio | ★ $44.18 | $106.25 |
| Revenue Growth | ★ 8.38 | N/A |
| 52 Week Low | $134.57 | $149.04 |
| 52 Week High | $345.72 | $251.71 |
| Indicator | ORCL | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 49.69 |
| Support Level | $185.89 | $222.07 |
| Resistance Level | $189.18 | $246.40 |
| Average True Range (ATR) | 8.30 | 3.63 |
| MACD | -0.08 | 0.91 |
| Stochastic Oscillator | 65.13 | 74.33 |
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.